Vectus Biosystems Limited (ASX:VBS)

Market Cap	4.43M
Revenue (ttm)	884.21K
Net Income (ttm)	-2.26M
Shares Out	53.33M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,335
Average Volume	42,794
Open	0.0830
Previous Close	0.0830
Day's Range	0.0830 - 0.0830
52-Week Range	0.0370 - 0.0880
Beta	0.80
RSI	79.42
Earnings Date	Aug 29, 2025

About Vectus Biosystems

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of r...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: VBS

Financial Performance

In 2024, Vectus Biosystems's revenue was 1.14 million, a decrease of -15.94% compared to the previous year's 1.35 million. Losses were -2.34 million, -32.07% less than in 2023.